Compare KMT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | IMCR |
|---|---|---|
| Founded | 1938 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.7B |
| IPO Year | 1994 | 2016 |
| Metric | KMT | IMCR |
|---|---|---|
| Price | $38.20 | $30.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $36.00 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 1.7M | 347.6K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,966,845,000.00 | $249,428,000.00 |
| Revenue This Year | $14.45 | $14.39 |
| Revenue Next Year | $7.95 | $8.19 |
| P/E Ratio | $52.42 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $17.30 | $23.15 |
| 52 Week High | $42.03 | $40.71 |
| Indicator | KMT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 39.51 |
| Support Level | $37.93 | N/A |
| Resistance Level | $41.89 | $34.86 |
| Average True Range (ATR) | 1.70 | 1.69 |
| MACD | -0.44 | -0.12 |
| Stochastic Oscillator | 32.99 | 10.94 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.